Compare Flagstar Bank NA (FLG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Neurocrine Biosciences Inc — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.69B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.1× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FLG | NBIX | |
|---|---|---|
Market Cap | $4.69B | $14.60B |
Volume | 6,174,553 | 1,075,694 |
Sector | Financials | Health |
52-Week High | $15.36 | $185.50 |
52-Week Low | $10.72 | $123.10 |
Typical Hold Time | 21 Days | 23 Days |
Enterprise Value | $15.23B | $14.61B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.30, down 2.25% today, with a bearish technical signal despite bullish oscillators. The stock shows mixed fundamentals with a high P/E of 376.67 but trades below book value (P/B 0.61). Recent Q2 2026 earnings missed expectations, though the company reported its third consecutive profitable quarter. Analyst consensus remains strongly bullish with a $17.07 price target and no sell ratings.
The outlook suggests potential upside from current depressed levels, supported by analyst optimism and strategic initiatives like the $250M share repurchase program. Key risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. The stock presents a value opportunity but requires careful monitoring of execution on profitability targets.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
